ArticleFrontiers in oncology2025
Solitary fibrous tumor of the chest wall with Doege-Potter syndrome: a case report.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To describe the management of a rare chest wall solitary fibrous tumor (SFT) complicated by Doege-Potter syndrome (DPS), emphasizing the critical roles of multidisciplinary consultation and preoperative vascular embolization in optimizing outcomes. Methods: A 56-year-old male presented with exertional dyspnea, dizziness, recurrent hypoglycemia, and hypokalemia. Contrast-enhanced computed tomography (CT) identified a large chest wall mass (19.2 × 13.3 × 21.6 cm), with biopsy confirming SFT. Multidisciplinary evaluation established a diagnosis of DPS. The patient underwent three cycles of neoadjuvant chemo-immunotherapy (albumin-bound paclitaxel, cisplatin, and anlotinib), followed by preoperative tumor vascular embolization. Surgical intervention involved en bloc tumor resection, left upper lobe wedge resection, and partial resection of the fifth rib. Results: Neoadjuvant therapy resulted in stable disease per RECIST 1.1 criteria. Preoperative embolization significantly reduced intraoperative blood loss to 200 mL, enabling an uneventful surgery. Postoperatively, hypoglycemia and hypokalemia resolved, and lung re-expansion was satisfactory. As of December 31, 2024, outpatient follow-up revealed no evidence of recurrence or metabolic abnormalities. Conclusions: This case highlights the importance of recognizing DPS as a rare manifestation of chest wall SFT and underscores the value of multidisciplinary strategies in managing large tumors. Preoperative vascular embolization effectively minimized surgical risks and corrected metabolic disturbances, facilitating successful resection. Further studies are warranted to refine therapeutic approaches for this uncommon clinical entity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.